101 related articles for article (PubMed ID: 18184634)
21. A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia.
Battaglia J; Houston JP; Ahl J; Meyers AL; Kaiser CJ
Clin Ther; 2005 Oct; 27(10):1612-8. PubMed ID: 16330297
[TBL] [Abstract][Full Text] [Related]
22. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
Sikich L; Hamer RM; Bashford RA; Sheitman BB; Lieberman JA
Neuropsychopharmacology; 2004 Jan; 29(1):133-45. PubMed ID: 14583740
[TBL] [Abstract][Full Text] [Related]
23. Internet in clinical research based on a pilot experience.
López-Carrero C; Arriaza E; Bolaños E; Ciudad A; Municio M; Ramos J; Hesen W
Contemp Clin Trials; 2005 Apr; 26(2):234-43. PubMed ID: 15837443
[TBL] [Abstract][Full Text] [Related]
24. The lesser of 2 evils: the ethics of placebo-controlled trials.
Streiner DL
Can J Psychiatry; 2008 Jul; 53(7):430-2. PubMed ID: 18674398
[No Abstract] [Full Text] [Related]
25. The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective.
Laughren TP
Eur Psychiatry; 2001 Nov; 16(7):418-23. PubMed ID: 11728855
[TBL] [Abstract][Full Text] [Related]
26. Optimal treatment allocation for placebo-treatment comparisons in trials with discrete-time survival endpoints.
Moerbeek M; Wong WK
Stat Med; 2015 Nov; 34(27):3490-502. PubMed ID: 26119759
[TBL] [Abstract][Full Text] [Related]
27. A historical review of placebo-controlled, relapse prevention trials in schizophrenia: The loss of clinical equipoise.
Lawrence RE; Appelbaum PS; Lieberman JA
Schizophr Res; 2021 Mar; 229():122-131. PubMed ID: 33234427
[TBL] [Abstract][Full Text] [Related]
28. [The value of publishing negative results from a randomized controlled trial: the Rosenheck's study].
Lima MS; Soares BG
Braz J Psychiatry; 2004 Jun; 26(2):135; author's reply 135-6. PubMed ID: 15517067
[No Abstract] [Full Text] [Related]
29. Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.
Pilla Reddy V; Kozielska M; Johnson M; Vermeulen A; de Greef R; Liu J; Groothuis GM; Danhof M; Proost JH
Clin Pharmacokinet; 2011 Jul; 50(7):429-50. PubMed ID: 21651312
[TBL] [Abstract][Full Text] [Related]
30. The power of the pilot.
Robb SL
J Music Ther; 2013; 50(1):3-5. PubMed ID: 23847861
[No Abstract] [Full Text] [Related]
31. Pharmacological treatment of patients with schizophrenia. Past and present problems and potential future therapy.
Johnson DA
Drugs; 1990 Apr; 39(4):481-8. PubMed ID: 2190791
[No Abstract] [Full Text] [Related]
32. Review: higher rates of attrition in antipsychotic treatment arms of placebo controlled trials than in trials with active comparators.
Stroup TS
Evid Based Ment Health; 2006 Aug; 9(3):70. PubMed ID: 16868189
[No Abstract] [Full Text] [Related]
33. The use of placebo-controlled clinical trials for the approval of psychiatric drugs: part I-statistics and the case for the "greater good".
Feifel D
Psychiatry (Edgmont); 2009 Mar; 6(3):41-3. PubMed ID: 19724754
[No Abstract] [Full Text] [Related]
34. Looking beyond Placebo-Controlled Trials.
Flohr C; Weidinger S
J Invest Dermatol; 2017 Jun; 137(6):1366-1367. PubMed ID: 28257792
[No Abstract] [Full Text] [Related]
35. Placebo in clinical trials.
Gupta U; Verma M
Perspect Clin Res; 2013 Jan; 4(1):49-52. PubMed ID: 23533982
[No Abstract] [Full Text] [Related]
36. Trace amine-associated receptor 1 (TAAR1) agonists for psychosis: protocol for a living systematic review and meta-analysis of human and non-human studies.
Siafis S; McCutcheon R; Chiocchia V; Ostinelli EG; Wright S; Stansfield C; Juma DO; Mantas I; Howes OD; Rutigliano G; Ramage F; Tinsdeall F; Friedrich C; Milligan L; Moreno C; Elliott JH; Thomas J; Macleod MR; Sena ES; Seedat S; Salanti G; Potts J; Cipriani A; Leucht S;
Wellcome Open Res; 2023; 8():365. PubMed ID: 38634067
[TBL] [Abstract][Full Text] [Related]
37. Are the results of open randomised controlled trials comparing antipsychotic drugs in schizophrenia biased? Exploratory meta- and subgroup analysis.
Leucht S; Siafis S; Schneider-Thoma J; Tajika A; Priller J; Davis JM; Furukawa TA
Schizophrenia (Heidelb); 2024 Feb; 10(1):17. PubMed ID: 38355616
[TBL] [Abstract][Full Text] [Related]
38. Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia.
Heres S; Cordes J; Feyerabend S; Schmidt-Kraepelin C; Musil R; Riedel M; Spellmann I; Langguth B; Landgrebe M; Fran E; Petcu C C; Hahn E; Ta TMT; Matei V; Dehelean L; Papava I; Leweke FM; van der List T; Tamasan SC; Lang FU; Naber D; Ruhrmann S; Wolff-Menzler C; Juckel G; Ladea M; Stefanescu C; Lautenschlager M; Bauer M; Zamora D; Horowitz M; Davis JM; Leucht S
Schizophr Bull; 2022 Nov; 48(6):1273-1283. PubMed ID: 35857811
[TBL] [Abstract][Full Text] [Related]
39. Are Randomized Controlled Trials on Pharmacotherapy and Psychotherapy for Positive Symptoms of Schizophrenia Comparable? A Systematic Review of Patient and Study Characteristics.
Bighelli I; Leucht C; Huhn M; Reitmeir C; Schwermann F; Wallis S; Davis JM; Leucht S
Schizophr Bull; 2020 Apr; 46(3):496-504. PubMed ID: 32275756
[TBL] [Abstract][Full Text] [Related]
40. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.
Huhn M; Nikolakopoulou A; Schneider-Thoma J; Krause M; Samara M; Peter N; Arndt T; Bäckers L; Rothe P; Cipriani A; Davis J; Salanti G; Leucht S
Lancet; 2019 Sep; 394(10202):939-951. PubMed ID: 31303314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
